Orchid Pharma Board Approves Q3 FY26 Results; Amalgamation Scheme Progresses
Orchid Pharma reported unaudited standalone and consolidated results for the quarter and nine months ended December 31, 2025. Standalone net sales were ₹20,726.70 lakhs for the quarter and ₹57,372.00 lakhs for nine months. Consolidated net sales were ₹20,726.70 lakhs and ₹57,372.00 lakhs respectively. The Board approved the results and noted progress on the amalgamation scheme with Dhanuka Laboratories Limited, with the next NCLT hearing on March 02, 2026.
The approval of financial results and progress on the amalgamation scheme are material events for the company. The detailed financial figures and the update on the NCLT proceedings are of significant interest to investors.
The announcement reports financial results and progress on corporate actions. While the results themselves are mixed, the overall tone is factual and procedural, lacking strong positive or negative indicators.
Orchid Pharma Limited announced the outcome of its Board Meeting held on February 11, 2026. The Board approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, along with the auditors' limited review reports.
The financial results for the nine months ended December 31, 2025, show a net sales of ₹57,372.00 lakhs for standalone operations and ₹57,372.00 lakhs for consolidated operations. Total income for the period stood at ₹61,566.56 lakhs (standalone) and ₹60,155.14 lakhs (consolidated). Expenses for the standalone operations amounted to ₹59,394.87 lakhs, leading to a profit before exceptional items and tax of ₹2,171.69 lakhs. Consolidated expenses were ₹59,620.88 lakhs, with a profit before exceptional items and tax of ₹534.26 lakhs.
For the quarter ended December 31, 2025, standalone net sales were ₹20,726.70 lakhs, and consolidated net sales were ₹20,726.70 lakhs. Total income was ₹21,785.70 lakhs (standalone) and ₹21,287.64 lakhs (consolidated). Standalone expenses were ₹21,656.86 lakhs, resulting in a profit before exceptional items and tax of ₹128.84 lakhs. Consolidated expenses were ₹21,791.01 lakhs, with a loss before exceptional items and tax of ₹503.37 lakhs.
The company also provided an update on its proposed amalgamation with its holding company, Dhanuka Laboratories Limited. The scheme has received 'No Objection' letters from both BSE Limited and the National Stock Exchange of India Limited. Shareholder and creditor approvals have been obtained, and the joint company petition is progressing with the National Company Law Tribunal (NCLT). The NCLT has scheduled the next hearing for March 02, 2026, after receiving reports from the Official Liquidator and Regional Director.
Additionally, the company reported that as of December 31, 2025, the entire net proceeds of ₹39,180 lakhs raised through Qualified Institutional Placement (QIP) have been received. The utilization of these funds is detailed, with significant amounts allocated to investment in OBPL (subsidiary) for manufacturing facilities and repayment of borrowings.
What to do with a filing like this
Orchid Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Orchid Pharma Limited. Read the original for the full detail.